Supplemental Figure 1



Figure S1. Amelioration of the clinical severity of donor mice upon GM-CSF treatment. Donor EAMG mice were treated with GM-CSF or PBS for 10 days. Day 0 corresponds to the initiation of treatment at the time of first booster immunization. A. Donor mice for suppression studies shown in Fig. 5A. *$p < 0.0005$ starting at day 10 ($n = 32$). B. Donor mice for suppression studies shown in Fig. 5C. *$p < 0.04$ starting at day 16 ($n = 20$) (also see Table S1).

Table1. Summary of treatment protocols and number of animals

Figure	Protocols	No. of animals/group in each experiment	No. of experiments	Pooled No. of animals in each group
1A	Donor mice: booster at Day 0, GM-CSF treatment started at Day 0 for 10 d.	10	2	20
4A	Booster at Day 0 and Day 24, AT at Day -1.	5	2	10
5A	Day 0: first AT (at 21d post booster1), second AT at Day 14, booster2 at Day 7.	8	2	16
5C	Booster at Day 0 and Day 30, AT at Day 10 and Day 40.	5	2	10
S1A	Donor mice: same as 1A	16	2	32
S1B	Donor mice: same as 1A	10	2	20

Mice were immunized with tAChR and given booster immunization every 24-30d. At least two booster immunizations were given except in donor mice (Fig. 1A, S1A and S1B) which received only one booster.

Table2. Absolute number of B cells and subsets ($1x10^5$)

Figure	Groups / Cells	Naïve	PBS/EAMG	GM-CSF/EAMG
1B	Total B cells	121±9.2	125±10	133±7.1
	$CD1d^{hi}CD5^+$	1.92±0.5	3.57±0.2* p <0.04	6.1±0.3** p < 0.0001 vs Naïve group; p < 0.00006 vs PBS/EAMG
	$CD19^+$ IL-10^+	2.0±0.2	3.6±0.3* p <0.006	6.4±0.6** p < 0.01 vs Naïve; p < 0.0001 vs. PBS/EAMG
1C	$CD19^+$ $CD40^+$		1.6±0.2	3.9±0.6* p <0.006 vs PBS/EAMG
	$CD19^+$ $MHCII^+$		3.1±0.3	4.0±0.5
	$CD19^+$ $CD23^+$		8.2±0.9	8.9±1.2
	$CD19^+$ IgM^+		7.3±0.6	7.1±0.4
	$CD19^+$ IgD^+		9.0±0.7	8.8±0.6

Absolute cell number was determined by using total cellularity, determined by trypan blue dye exclusion and percentage of $CD19^+$ or B cell subsets. Total splenocytes ranged from 6.4 $x10^7$ to $8.6x10^7$. P values listed were based on comparison with Naïve group unless otherwise specified (n = 6 each).

Table3. Absolute number of Tregs and proliferating $CD4^+$ T cells ($1x10^5$)

Figure	Groups / Cells	CTRL (no AT)	$CD1d^{hi}CD5^+$ (PBS/EAMG)	$CD1d^{hi}CD5^+$ (GM-CSF/EAMG)
4E upper panel	Proliferating $CD4^+$	1.72±0.05	1.38±0.06* p <0.001	0.79±0.09** p < 0.0001 vs. CTRL; p < 0.001 vs. PBS/EAMG
4E lower panel	Total $CD4^+$	116±3.1	113±2.5	117±1.7
	$CD25^+$ $Foxp3^+$	8.5±0.6	11.2±0.8* p <0.03	14.7±0.3** p < 0.00001 vs CTRL; p < 0.002 vs. PBS/EAMG
5E upper panel	Proliferating $CD4^+$	1.25±0.15	0.71±0.06* p <0.002	0.53±0.05** p <0.00005 vs CTRL; p<0.0006 vs. PBS/EAMG
5E lower panel	Total $CD4^+$	116±2.2	114±3.1	115±2.4
	$CD25^+$ $Foxp3^+$	10.7±0.2	12.9±0.3* p <0.0003	17.5±1.1** p <0.0002 vs CTRL; p<0.005 vs. PBS/EAMG

Absolute cell number was determined by using total cellularity, determined by trypan blue dye exclusion and percentage of $CD4^+$ or $CD4^+CD25^+$ $Foxp3^+$ cells. For all T cell proliferation, $5x10^5$/ well of CFSE labeled $CD4^+$ cells were used. Total splenocytes ranged from 8.4 $x10^7$ to $10x10^7$. P values listed were based on comparison with CTRL unless otherwise specified (n = 6 each).